Delivery of antifungal agents using bioactive and nonbioactive bone cements

Annals of Pharmacotherapy

Volumn 43, Issue 10, 2009, Pages 1606-1615

  Sealy, Patricia I ^a   Nguyen, Cam ^b   Tucci, Michelle ^c   Benghuzzi, Ham ^d,e   Cleary, John D ^f  

^a UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d Department of Diagnostic and Clinical Health Sciences ^*

^e UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^f UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

tricalcium phosphate; Antifungal agents; Bone cement; Fungal osteomyelitis; Hydroxyapatite; MG 63 osteoblast like cells; Polymethylmethacrylate

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BONE CEMENT; CALCIUM; CALCIUM PHOSPHATE; FLUCONAZOLE; FLUCYTOSINE; HYDROXYAPATITE; MICAFUNGIN; MICROSPHERE; POLY(METHYL METHACRYLATE); TERBINAFINE; TISSUE CULTURE MEDIUM;

ANTIFUNGAL ACTIVITY; ARTICLE; BIODEGRADABLE IMPLANT; CALCIUM BLOOD LEVEL; CERAMICS; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ELUTION; HEALTH CARE COST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OSTEOBLAST; OSTEOMYELITIS; PRIORITY JOURNAL; SUPERNATANT; SURGICAL RISK;

ANIMALS; ANTIFUNGAL AGENTS; BIOCOMPATIBLE MATERIALS; BONE CEMENTS; CALCIUM; CALCIUM PHOSPHATES; CATTLE; CELLS, CULTURED; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; HUMANS; HYDROXYAPATITES; OSTEOBLASTS; OSTEOMYELITIS; POLYMETHYL METHACRYLATE;

EID: 70449489668     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M143     Document Type: Article

References (48)

1. Miller DJ, Mejicano GC. Vertebral osteomyelitis due to Candida species: case report and literature review. Clin Infect Dis 2001;33:523-530
2. Wilson C. Orthopedic infections. In: Skinner HB, ed. Current diagnosis and treatment in orthopedics, 3rd ed. New York, NY: The McGraw-Hill Companies, 2003:414-448
3. Blot S, Vandewoude K. Management of invasive candidiasis in critically ill patients. Drugs 2004;64:2159-2175 (Pubitemid 39382207)
4. Ostrosky-Zeichner L, Rex JH, Bennett J, Kullberg BJ. Deeply invasive candidiasis. Infect Dis Clin North Am 2002;16:821-835
5. Frazier DD, Campbell DR, Garvey TA, Wiesel S, Bohlman HH, Eismont FJ. Fungal infections of the spine. Report of eleven patients with long-term follow-up. J Bone Joint Surg Am 2001;83A:560-565
6. Berbari EF, Steckelberg JM, Osmon DR. Other forms of osteomyelitis: specific hosts, unusual locations, or unusual organisms. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases: part II. http://mdconsult.com/das/book/body/74930253-/605019366/1259/764.html?SEQN; 2005 (accessed 2007 Jul 20).
7. Garvin K, Feschuk C. Polylactide-polyglycolide antibiotic implants. Clin Orthop Relat Res 2005;437:105-110
8. Collignon PJ, Sorrell TC. Disseminated candidiasis: evidence of a distinctive syndrome in heroin abusers. Br Med J (Clin Res Ed) 1983;287:861-862
9. Merrer J, Dupont B, Nieszkowska A, De Jonghe B, Outin H. Candida albicans prosthetic arthritis treated with fluconazole alone. J Infect 2001;42:208-209
10. Marrie TJ, Costerton JW. Mode of growth of bacterial pathogens in chronic polymicrobial human osteomyelitis. J Clin Microbiol 1985;22:924-933
11. Benoit MA, Mousset B, Delloye C, Bouillet R, Gillard J. Antibioticloaded plaster of Paris implants coated with poly lactide-co-glycolide as a controlled release delivery system for the treatment of bone infections. Int Orthop 1997;21:403-408 (Pubitemid 28055132)
12. Pappas PG, Rex JH, Sobel JD, et al. Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-189
13. Lazzarini L, Mader JT, Calhoun JH. Osteomyelitis in long bones. J Bone Joint Surg Am 2004;86A:2305-2318
14. Parsons B, Strauss E. Surgical management of chronic osteomyelitis. Am J Surg 2004;188:57-66.
15. Winkler H, Janata O, Berger C, Wein W, Georgopoulos A. In vitro release of vancomycin and tobramycin from impregnated human and bovine bone grafts. J Antimicrob Chemother 2000;46:423-428
16. Dahners LE, Funderburk CH. Gentamicin-loaded plaster of Paris as a treatment of experimental osteomyelitis in rabbits. Clin Orthop Relat Res 1987;219:278-282
17. Schmidt C, Wenz C, Nies B, Moll F. Antibiotic in vivo/in vitro release, histocompatibility and biodegradation of gentamicin implants based on lactic acid polymers and copolymers. J Control Release 1995;37:83-94.
18. Bajpai PK, Benghuzzi HA. Ceramic systems for long-term delivery of chemicals and biologicals. J Biomed Mater Res 1988;22:1245-1266
19. Benghuzzi HA, England BG, Bajpai PK. Tricalcium phosphate amino acid capsules as a drug delivery system for steroid hormones. Biomed Sci Instrum 1991;27:197-203.
20. Benghuzzi HA, England BG, Bajpai PK. Controlled release of hydrophilic compounds by resorbable and biodegradable ceramic drug delivery devices. Biomed Sci Instrum 1992;28:179-182
21. Stallmann HP, Faber C, Bronckers AL, Nieuw Amerongen AV, Wuisman PI. In vitro gentamicin release from commercially available calcium- phosphate bone substitutes influence of carrier type on duration of the release profile. BMC Musculoskelet Disord 2006;7:18.
22. Benghuzzi H, Tucci M, Russell G, Ragab A, Graves M, Conflitti J. Targeted sustained delivery of tobramycin at the site of a femoral osteotomy. Biomed Sci Instrum 2006;42:530-535 (Pubitemid 43911309)
23. Kirui PK, Cameron J, Benghuzzi HA, et al. Effects of sustained delivery of thymoquinone on bone healing of male rats. Biomed Sci Instrum 2004;40:111-116 (Pubitemid 38595941)
24. Adah F, Benghuzzi H, Tucci M, Russell G, England B. Cholesterol production inhibitor (statin) increased bone healing in surgically created femoral defect in an animal model. Biomed Sci Instrum 2007;43:95-103. (Pubitemid 46668192)
25. Silverman LD, Lukashova L, Herman OT, Lane JM, Boskey AL. Release of gentamicin from a tricalcium phosphate bone implant. J Orthop Res 2007;25:23-29 (Pubitemid 46070728)
26. Wichelhaus TA, Dingeldein E, Rauschmann M, et al. Elution characteristics of vancomycin, teicoplanin, gentamicin and clindamycin from calcium sulphate beads. J Antimicrob Chemother 2001;48:117-119 (Pubitemid 32684735)
27. Gitelis S, Brebach GT. The treatment of chronic osteomyelitis with a biodegradable antibiotic-impregnated implant. J Orthop Surg (Hong Kong) 2002;10:53-60. (Pubitemid 35332424)
28. Jiranek WA, Hanssen AD, Greenwald AS. Antibiotic-loaded bone cement for infection prophylaxis in total joint replacement. J Bone Joint Surg Am 2006;88:2487-2500
29. McKee MD, Wild LM, Schemitsch EH, Waddell JP. The use of an antibiotic-impregnated, osteoconductive, bioabsorbable bone substitute in the treatment of infected long bone defects: early results of a prospective trial. J Orthop Trauma 2002;16:622-627
30. Benghuzzi HA, Barbaro RM, Bajpai PK. Sustained delivery of 3Hthymidine by means of ceramic capsules in rats. Biomed Sci Instrum 1989;25:169-177
31. Jorgensen JH, Alexander GA, Graybill JR, Drutz DJ. Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid. Antimicrob Agents Chemother 1981;20:59-62. (Pubitemid 11002438)
32. Bodet CA 3rd, Jorgensen JH, Drutz DJ. Simplified bioassay method for measurement of flucytosine or ketoconazole. J Clin Microbiol 1985;22:157-160
33. Reference method for broth dilution antifungal susceptibility testing of yeasts-second edition; approved standard M27-A2. Wayne, PA: Clinical Laboratory Standards Institute, 2002.
34. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000;44:57-62.
35. Buranapanitkit B, Oungbho K, Ingviya N. The efficacy of hydroxyapatite composite impregnated with amphotericin B. Clin Orthop Relat Res 2005;437:236-241 (Pubitemid 41099093)
36. Bruce AS, Kerry RM, Norman P, Stockley I. Fluconazole-impregnated beads in the management of fungal infection of prosthetic joints. J Bone Joint Surg (Br) 2001;83:183-184
37. Andrews JM. Microbiological assays. In: Reeves DS, Wise R, Andrews JM, White LO, eds. Clinical antimicrobial assays. New York, NY: Oxford University Press Inc., 1999:35-44.
38. Amphotericin B. In: Trissel LA. Handbook on injectable drugs. 12th ed. Bethesda, MD: American Society of Health-System Pharmacists, 2003: 113.
39. Rx List. Mycamine. www.rxlist.com/cgi/generic/mycamine (accessed 2008 Jul 7).
40. Odabasi Z, Paetznick V, Rex JH, Ostrosky-Zeichner L. Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother 2007;51:4214-4216
41. Paderu P, Garcia-Effron G, Balashov S, Delmas G, Park S, Perlin DS. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 2007;51:2253-2256 (Pubitemid 46903131)
42. Wiederhold NP, Najvar LK, Bocanegra R, Molina D, Olivo M, Graybill JR. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 2007;51:1616-1620
43. Fini M, Giavaresi G, Aldini NN, et al. A bone substitute composed of polymethylmethacrylate and alpha-tricalcium phosphate: results in terms of osteoblast function and bone tissue formation. Biomaterials 2002;23:4523-4531 (Pubitemid 36151604)
44. Miclau T, Edin ML, Lester GE, Lindsey RW, Dahners LE. Bone toxicity of locally applied aminoglycosides. J Orthop Trauma 1995;9:401-406
45. Edin ML, Miclau T, Lester GE, Lindsey RW, Dahners LE. Effect of cefazolin and vancomycin on osteoblasts in vitro. Clin Orthop Related Res 1996;333:245-251
46. Arias F, Mata-Essayag S, Landaeta ME, et al. Candida albicans osteomyelitis: case report and literature review. Int J Infect Dis 2004;8:307-314
47. Schilling A, Seibold M, Mansmann V, Gleissner B. Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/ posaconazole therapy. Med Mycol 2008;46:79-83.
48. Neale TJ, Muir JC, Mills H, Horne JG, Jones MR. Candida albicans vertebral osteomyelitis in chronic renal failure. Postgrad Med J 1987;63:695-698